Eli Lilly and Company (NYSE:LLY) PT Raised to $900.00 at JPMorgan Chase & Co.

Eli Lilly and Company (NYSE:LLY) had its price objective upped by analysts at JPMorgan Chase & Co. from $850.00 to $900.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 22.45% from the stock’s previous close.

A number of other brokerages have also commented on LLY. Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Trading Down 2.8 %

Shares of NYSE:LLY traded down $20.94 during midday trading on Wednesday, reaching $734.97. The company had a trading volume of 4,535,213 shares, compared to its average volume of 3,087,178. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The firm has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a fifty day simple moving average of $761.75 and a two-hundred day simple moving average of $670.56.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the company posted $1.62 EPS. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 13.49 earnings per share for the current year.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently bought and sold shares of the stock. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $27,000. Tidemark LLC acquired a new position in Eli Lilly and Company in the fourth quarter worth $29,000. Core Wealth Advisors Inc. increased its position in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares in the last quarter. Finally, Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.